Evidence map›Paper›PMID 39253464›Full record

ArticlebioRxiv : the preprint server for biology2024

Modulation of antigen delivery and lymph node activation in non-human primates by saponin adjuvant SMNP.

Parisa Yousefpour, Yiming J Zhang, Laura Maiorino, Mariane B Melo, Mariluz A Arainga Ramirez, Sidath C Kumarapperuma, Peng Xiao, Murillo Silva, Na Li, Katarzyna K Michaels and 13 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Parisa YousefpourKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-0431-8131
Yiming J ZhangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-8102-3815
Laura MaiorinoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Mariane B MeloKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Mariluz A Arainga RamirezNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
Sidath C KumarapperumaResearch Imaging Institute, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
Peng XiaoNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
Murillo SilvaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Na LiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Katarzyna K MichaelsKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Erik GeorgesonRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University; Cambridge, MA 02139 USA.
Saman EskandarzadehRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University; Cambridge, MA 02139 USA.
Michael KubitzRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University; Cambridge, MA 02139 USA.
Bettina GroschelRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University; Cambridge, MA 02139 USA.
Kashif QureshiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jane FontenotNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
Lars HangartnerConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute; La Jolla, CA 92037 USA.
Rebecca NedellecDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
J Christopher LoveKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Dennis R BurtonRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University; Cambridge, MA 02139 USA.
William R SchiefRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University; Cambridge, MA 02139 USA.
Francois J VillingerNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA.
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-8637-1405

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Virology and ImmunologyP01AI048240 · NIAID · UNIVERSITY OF WASHINGTON · PI RUPRECHT, RUTH MARGRIT · 2000 to 2020
$46.7M
Maximizing germinal centers and somatic hypermutation to HIV Env immunogensR37AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Shane P Crotty, Darrell J Irvine · 2021 to 2026
$5.4M
Maximizing germinal centers and somatic hypermutation to HIV Env immunogensR01AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2016 to 2020
$4.3M
Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA RepliconsR01AI176533 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Gaurav Das Gaiha · 2023 to 2026
$3.5M
NIAID NIH HHS P01 AI048240NIAID NIH HHS R01 AI125068NIAID NIH HHS R01 AI176533NIAID NIH HHS R37 AI125068NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Saponin-based vaccine adjuvants are potent in preclinical animal models and humans, but their mechanisms of action remain poorly understood. Here, using a stabilized HIV envelope trimer immunogen, we carried out studies in non-human primates (NHPs) comparing the most common clinical adjuvant alum with Saponin/MPLA Nanoparticles (SMNP), a novel ISCOMs-like adjuvant. SMNP elicited substantially stronger humoral immune responses than alum, including 7-fold higher peak antigen-specific germinal center B cell responses, 18-fold higher autologous neutralizing antibody titers, and higher levels of antigen-specific plasma and memory B cells. PET-CT imaging in live NHPs showed that, unlike alum, SMNP promoted rapid antigen accumulation in both proximal and distal lymph nodes (LNs). SMNP also induced strong type I interferon transcriptional signatures, expansion of innate immune cells, and increased antigen presenting cell activation in LNs. These findings indicate that SMNP promotes multiple facets of the early immune response relevant for enhanced immunity to vaccination.

Identifiers

PMID39253464
PMCPMC11383317

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.